NCT07102394 2026-02-17
Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1
Johns Hopkins University
Phase 1 Recruiting
Clinical Trials
7 trialsNCT02211768 2025-12-24
Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT06961565 2025-12-04
PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
Pasithea Therapeutics Corp.
Phase 1 Recruiting
NCT05438290 2024-05-06
DPCP to Treat Cutaneous Neurofibromas Associated With NF1
Icahn School of Medicine at Mount Sinai
Phase 1 Completed
NCT05107037 2021-11-04
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of TQ-B3234 in Patients With Type I Neurofibromatosis
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT01682811 2021-06-18
Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)
Medical College of Wisconsin
Phase 1 Completed
NCT01031901 2012-02-27
Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)
The University of Texas Health Science Center, Houston
Phase 1 Completed